MedTrace Logo

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

NCT04911582 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-02-28

No results posted yet for this study

Summary

Acute, double-blinded, randomized, cross-over cafestol intervention study with fifteen participants with a large waist circumference participating in three OGTTs.

Conditions

  • Obesity, Abdominal

Interventions

DIETARY_SUPPLEMENT

Cafestol 12 mg

Capsule with 12 mg cafestol

DIETARY_SUPPLEMENT

Placebo

Placebo capsule without cafestol

DIETARY_SUPPLEMENT

Cafestol 6 mg

Capsule with 6 mg cafestol

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2021-09-16
Completion
2021-09-16

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04911582 on ClinicalTrials.gov